The Headlines You Saw Today
- The FDA granted full approval to Moderna’s Spikevax for children aged 6 months to 11 years at increased risk, no longer under emergency use authorization.
- Despite canceled routine vaccine recommendations for healthy kids and pregnant women, CDC still allows COVID vaccination if parents and doctors agree it’s needed.
- Lower age FDA signoff means Spikevax is on the childhood vaccine schedule, protected under the 1986 National Childhood Vaccine Injury Act.
- Moderna shares surged between 2%–4.5% today—noticeable market movement tied to approval news.
Why This Should Alarm You
Let’s lay this out plainly:
- The body’s natural immune response matters. Vaccines interfere early in life—before kids experience mild viruses naturally. Yet Moderna’s approval pushes them when long-term data is slim.
- Kids not at risk. Healthy children face minimal threat from COVID. Why inject relatively new mRNA technology into infants and toddlers without rigorous long-term safety data? The riskbenefit doesn’t add up.
- Financial incentives in play. Moderna’s stock spike isn’t coincidental. Every new approval means more guaranteed revenue—as promised under the childhood immunization schedule, where insurance coverage is automatic.
The Money Behind the Medicine
Let’s connect the dots:
- With Spikevax now fully approved for young children, coverage is automatic—and litigation protections kick in under the 1986 Vaccine Act.
- Shareholders celebrated accordingly: Moderna stock climbed 4.5% on the day of FDA approval.
- That kind of market reaction isn’t about public health—it’s about revenue assurance. Turning kids into recurring vaccine customers ensures a stable—and protected—income stream.
What No One’s Talking About
- New Moderna mRNA vaccines such as mNEXSPIKE are engineered to be lower dose—but still carry all the usual unknowns of long-term mRNA exposure.
- Despite CDC dropping universal COVID shot recommendations for healthy kids and pregnant moms in May, this pediatric approval contradicts that direction. It effectively reinstates pediatric dosing, but with full liability immunity for manufacturers.
Why It Should Matter to You
If you’re a parent, pregnant, or a human being capable of health decision-making, ask yourself:
- Does the vaccine control outweigh the child’s own developing immune wisdom?
- Are corporations writing policies that turn healthy babies and toddlers into guaranteed product users?
- Who benefits from pushing full approval when societal risk is so low?
Bottom Line: It’s Not Medicine. It’s Business Dressed as Medicine
Moderna’s full pediatric approval is less about protecting children from COVID—more about bolstering financial protections for a pharmaceutical giant. It drags children into the vaccine schedule—not because they need it, but because it’s safe from legal and financial challenge.
At The Wellness Way, we reject top-down mandates and believe the body’s innate resilience deserves respect. You deserve choices—not automatic inclusion in a one-size-fits-most vaccine calendar.
Protect health freedom—especially for the littlest among us.
